四种直接口服抗凝药在亚洲非瓣膜性房颤患者中的有效性与安全性
基于台湾全民健康保险研究数据库2012年6月1日至2017年12月31日的全国性回顾性队列研究,纳入服用艾多沙班、阿哌沙班、利伐沙班、达比加群或华法林的非瓣膜性房颤患者,采用倾向评分加权平衡组间协变量。结果显示艾多沙班、阿哌沙班和利伐沙班较华法林缺血性卒中/系统性栓塞风险更低,所有DOAC大出血风险均低于华法林;阿哌沙班大出血风险低于利伐沙班和达比加群,艾多沙班与阿哌沙班大出血风险相当。上述降低在慢性肾脏病、年龄≥75岁、二级卒中预防或CHA2DS2-VASc评分≥4的高危亚组中持续存在,低剂量方案比较结果与主分析一致。
要点
- 所有四种DOAC较华法林大出血风险更低,艾多沙班、阿哌沙班、利伐沙班较华法林缺血性卒中/系统性栓塞风险更低。
- 阿哌沙班大出血风险低于利伐沙班和达比加群;艾多沙班与阿哌沙班大出血风险相当。
- 高危亚组(慢性肾脏病、年龄≥75岁、二级卒中预防、CHA2DS2-VASc≥4)中DOAC降低血栓栓塞/大出血风险的优势持续存在。
- 低剂量艾多沙班15-30 mg/d、阿哌沙班2.5 mg bid、利伐沙班10-15 mg/d、达比加群110 mg bid与华法林比较的有效性/安全性结果与主分析一致。
适用人群与场景
- 台湾全民健康保险研究数据库2012年6月1日至2017年12月31日覆盖的非瓣膜性房颤患者,服用艾多沙班(n=4,577)、阿哌沙班(n=9,952)、利伐沙班(n=33,022)、达比加群(n=22,371)或华法林(n=19,761)。
- 高危亚组包括慢性肾脏病、老年(年龄≥75岁)、二级卒中预防或CHA2DS2-VASc评分≥4的患者。
诊断标准与关键阈值
- CHA2DS2-VASc评分包括充血性心力衰竭、高血压、年龄≥75岁、糖尿病、既往卒中/短暂性脑缺血发作、血管疾病、年龄65-74岁和女性性别。
处置流程与药物剂量
- 低剂量方案:艾多沙班15-30 mg/d,2,924例(64%)接受。
- 低剂量方案:阿哌沙班2.5 mg bid,6,359例(64%)接受。
- 低剂量方案:利伐沙班10-15 mg/d,31,108例(94%)接受。
- 低剂量方案:达比加群110 mg bid,19,821例(89%)接受。
研究设计与关键结果
- 研究类型:全国性回顾性队列研究,基于台湾全民健康保险研究数据库,采用倾向评分加权平衡协变量,随访至研究结局发生或研究截止日期。
- 艾多沙班、阿哌沙班和利伐沙班较华法林缺血性卒中/系统性栓塞风险更低;所有DOAC较华法林大出血风险更低。
- 阿哌沙班大出血风险低于利伐沙班和达比加群;艾多沙班与阿哌沙班大出血风险相当。
- 四种DOAC降低血栓栓塞/大出血风险的优势在慢性肾脏病、年龄≥75岁、二级卒中预防或CHA2DS2-VASc≥4的高危亚组中持续存在。
- 低剂量DOAC与华法林比较的有效性/安全性结果与主分析一致。
证据类型、等级与局限
- 证据类型:基于台湾全民健康保险研究数据库的全国性回顾性队列研究。
- 局限:原文未报告局限性
对床旁实践的改变
- 在亚洲非瓣膜性房颤患者中,四种DOAC较华法林相比血栓栓塞风险相当或更低、大出血风险更低,此结果在高危亚组和低剂量方案比较中一致(作者结论)。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Whether four direct oral anticoagulants (DOACs) are superior to warfarin in Asian patients with nonvalvular atrial fibrillation (NVAF) remains unclear.
METHODS: This nationwide retrospective cohort study was based on data from Taiwan's National Health Insurance Research Database from June 1, 2012, to December 31, 2017, covering patients with NVAF taking edoxaban (n = 4,577), apixaban (n = 9,952), rivaroxaban (n = 33,022), dabigatran (n = 22,371), and warfarin (n = 19,761). Propensity score weighting was used to balance covariates across study groups. Patients were followed up until occurrence of study outcomes or end date of study.
RESULTS: Edoxaban, apixaban, and rivaroxaban were associated with a lower risk of ischemic stroke/systemic embolism than warfarin. All DOACs had a lower risk of major bleeding than warfarin. Apixaban was associated with a lower risk of major bleeding than rivaroxaban and dabigatran, whereas the risk of major bleeding was comparable between edoxaban and apixaban. The reduced risks of thromboembolism/major bleeding for the four DOACs persisted in high-risk subgroups, including those with chronic kidney disease, elderly patients (age ≥ 75 years), secondary stroke prevention, or CHA2DS2-VASc score (congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, previous stroke/transient ischemic attack, vascular disease, age 65-74 years, and female sex) ≥ 4. A total of 2,924 (64%), 6,359 (64%), 31,108 (94%), and 19,821 (89%) patients received low-dose edoxaban (15-30 mg/d), apixaban (2.5 mg bid), rivaroxaban (10-15 mg/d), and dabigatran (110 mg bid), respectively. The effectiveness/safety outcomes with the four low-dose DOACs compared with warfarin were consistent with the main analysis.
CONCLUSIONS: In the largest real-world practice study among Asian patients with NVAF, four DOACs were associated with a comparable or lower risk of thromboembolism, and a lower risk of bleeding than warfarin. There was consistency even among high-risk subgroups and whether standard-or low-dose regimens were compared.
参考来源
- Chan YH, Lee HF, See LC, et al. Effectiveness and Safety of Four Direct Oral Anticoagulants in Asian Patients With Nonvalvular Atrial Fibrillation. Chest. 2019. PMID: 31103697. doi:10.1016/j.chest.2019.04.108
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。